Prevention by L-α-phosphatidylcholine of antifungal activity in vitro of liposome-encapsulated imidazoles determined by using time-killing curves

International Journal of Antimicrobial Agents

Volumn 15, Issue 1, 2000, Pages 43-48

  De Logu, Alessandro ^a   Fadda, Anna Maria ^b   Pellerano, Maria Luisa ^a   Diana, Giorgia ^a   Schivo, Maria Laura ^a  

^a Dipto Sci Chirurgiche T   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Antifungal activity; Candida albicans; Imidazole derivatives; Ketoconazole; Miconazole; Multilamellar vesicles (MLV); Small unilamellar vesicles (SUV)

Indexed keywords

AMPHOTERICIN B; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; LIPOSOME; MICONAZOLE; PHOSPHATIDYLCHOLINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; CURVE FITTING; DRUG FORMULATION; ENCAPSULATION; FUNGICIDAL ACTIVITY; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CHOLESTEROL; KETOCONAZOLE; LIPOSOMES; MICONAZOLE; PHOSPHATIDYLCHOLINES;

EID: 0034039803     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00124-2     Document Type: Article

References (22)

1. Gigliotti F., Shenep J.L., Lott L., Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J. Infect. Dis. 156:1987;784-789.
2. Caillot D., Casasnovas O., Solary E. et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidemia in neutropenic patients. J. Antimicrob. Chemother. 31:1993;161-169.
3. Caillot D., Reny G., Solary E. et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J. Antimicrob. Chemother. 33:1994;603-613.
4. Moreau P., Milpied N., Fayette N., Ramée J.F., Harousseau J.L. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30:1992;535-541.
5. Gulati M., Bajad S., Singh S., Ferdous A.J., Singh M. Development of liposomal amphotericin B formulation. J. Microencapsul. 15:1998;137-151.
6. Fainstein V., Bodey G.P. Cardiorespiratory toxicity due to miconazole. Ann. Intern. Med. 93:1980;432-433.
7. Dismukes W.E., Stamm A.M., Graybill J.R. et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. Ann. Intern. Med. 98:1983;13-20.
8. Berenguer J., Muñoz P., Parras F., Baca-Fernández V., Hernández-Sampelayo T., Bouza E. Treatment of deep mycoses with liposomal amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 13:1994;504-507.
9. Anaissie E., Paetznick V., Proffitt R., Adler-Moore J., Bodey G.P. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 10:1991;665-668.
10. Lee J.W., Amantea M.A., Francis P.A. et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38:1994;713-718.
11. Wasan K.M., Brazeau G.A., Keyhani A., Hayman A.C., Lopez-Berestein G. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37:1993;246-250.
12. Wasan K.M., Rosenblum M.G., Cheung L., Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38:1994;223-227.
13. Szoka F.C., Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 31:1987;421-429.
14. Singh M., Singh M.P., Maiti S.N., Gandhi A., Micetich R.G., Atwal H. Preparations of liposomal fluconazole and their in vitro antifungal activity. J. Microencapsulation. 10:1993;229-236.
15. Hopfer R.L., Mills K., Metha R., Lopez-Berestein G., Fainstein V., Juliano R.L. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25:1984;387-389.
16. De Logu A., Fadda A.M., Anchisi C. et al. Effects of in-vitro activity of miconazole and ketoconazole in phospholipid formulations. J. Antimicrob. Chemother. 40:1997;731-734.
17. Metha R.T., Keyhani A., McQueen T.J., Rosenbaum B., Rolston K.V., Tarrand J.J. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. Antimicrob. Agents Chemother. 37:1993;2584-2587.
18. Swenson C.R., Popescu M.C., Ginsberg R.S. Preparation and use of liposomes in the treatment of microbial infections. Crit. Rev. Microbiol. 15:1988;S1-S31.
19. Pahls S., Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J. Infect. Dis. 169:1994;1057-1061.
20. Janoff A.S., Boni L.T., Popescu M.C. et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA. 85:1988;6122-6126.
21. Perkins W.R., Minchey S.R., Boni L.T. et al. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta. 1107:1992;271-282.
22. Ahmad I., Sarkar A.K., Bachhawat B.K. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B. Biotechnol. Appl. Biochem. 12:1990;550-556.